Exhibit A

1

UNITED STATES DISTRICT COURT 1 FOR THE DISTRICT OF NEW JERSEY 2 CIVIL ACTION NUMBER: 3 19-md-02875-RBK-JS 4 IN RE: VALSARTAN PRODUCTS LIABILITY LITIGATION TELEPHONIC STATUS and 5 **DISCOVERY CONFERENCE** WITH RULINGS ON PLAINTIFFS' 6 CUSTODIAN LISTS AND DOCUMENT REQUESTS 7 Mitchell H. Cohen Building & U.S. Courthouse 8 4th & Cooper Streets Camden, New Jersey 08101 9 December 18, 2019 Commencing at 11:07 a.m. 10 11 BEFORE: THE HONORABLE JOEL SCHNEIDER, UNITED STATES MAGISTRATE JUDGE 12 13 A P P E A R A N C E S (via telephone): 14 MAZIE SLATER KATZ & FREEMAN, LLC 15 BY: ADAM M. SLATER, ESQUIRE 103 Eisenhower Parkway Roseland, New Jersey 07068 16 For the Plaintiff 17 18 GOLOMB & HONIK, P.C. BY: RUBEN HONIK, ESQUIRE DAVID J. STANOCH, ESQUIRE 19 1835 Market Street, Suite 2900 20 Philadelphia, Pennsylvania 19103 For the Plaintiff 21 22 23 Carol Farrell, Official Court Reporter cfarrell.crr@gmail.com 24 856-318-6100 25 Proceedings recorded by mechanical stenography; transcript produced by computer-aided transcription.

1

2

5

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

interest. There is tremendous public interest in this case. It has enormous public health consequences -- whether a very popular drug supplied in the United States was contaminated or not. Given the public interest and the health and welfare implications, when it comes to evaluating the burden to the defendant in the case, the Court has to take that into consideration. It's not just a simple matter of dollars and cents, but on this particular issue, it really isn't a dollar and cents issue as far as the Court's concerned. The Court's main concern is, again, whether or not, if we add this person to a pretty hefty custodian list, it's likely or probable that we're going to find something that is not otherwise going to be produced. I don't think that's the case. I could be proven wrong in the future. If there is evidence in that regard, so be it. But in terms of a custodian search for documents, the Court sustains Mr. Goldberg's objections and will remove Mr. Chen from the list, and will approve the list absent his name. I'll make it clear. The Court is not ruling at this time whether or not Mr. Chen is an appropriate deponent. That's a completely different evaluation that the Court has to consider at the relevant time. If defendant wants to depose

Mr. Chen, we'll deal with the issue at that point. But in no

way, shape, or form should the Court's ruling as to whether or

```
not Mr. Chen is an appropriate custodian be deemed as a ruling
 1
   as to whether or not he may be deposed in the case.
 3
             So that's the Court's ruling as to Mr. Chen. I'm
 4
    going to approve Exhibit B with the removal of his name from
 5
    the list.
 6
             MR. SLATER: Your Honor, we need to substitute
 7
    somebody for him.
 8
             THE COURT: Do you have a name?
 9
             MR. SLATER: I would need a couple hours or an hour
    or two just so I can talk to somebody, to some people, and
10
    just figure out who to substitute.
11
             THE COURT: Okay. Could you e-mail me that name,
12
13
   Mr. Slater, and I'll add it to Exhibit B, so I can enter this
14
   order?
15
             MR. SLATER: Of course.
16
             THE COURT: Thank you.
17
             All right. Is the only issue left the issues
    regarding the document requests?
18
19
             MR. SLATER: Your Honor --
             MR. RUBENSTEIN: Your Honor, very quickly, this is --
20
           This is Brian Rubenstein for the Teva defendants.
21
22
             There is no objections with respect to Exhibit D, the
    list of Teva custodians, but there were just a few names that
23
   were misspelled, so we can submit a revised list with the
24
25
   proper spellings of those few names.
```